The second one! India approves fapilawi for use in patients with mild to moderate new coronary pneumonia.

Glenmark, an Indian pharmaceutical company, recently announced that its FabiFlu (favipiravir) has been approved by India's drug regulator for the treatment of patients with mild to moderate new coronary pneumoniajust reported yesterday that two Redsseve generics developed by Cipla and Hetero have been approved to treat patients with severe new coronary pneumoniaFabiFlu is india's first oral antiviral drug approved for the treatment of mild to moderate new coronal pneumoniarelated reading: Redsewe generic sisave approved in India, with total treatment costs as low as $195FabiFlu's approval is based on clinical evidence shown by Fabilave in patients with mild to moderate new coronary pneumoniaThe data showed that the drug can quickly reduce viral load within four days and show rapid symptoms and radiological improvementsIn addition, fapilavir had an 88% clinical improvement rate in patients with mild to moderate new coronary pneumoniaAnd the drug is given by orthereation, which is a more convenient treatment option than other intravenous drugsapproval comes at a time when india's new crown pneumonia cases are on the rise, putting enormous pressure on the country's health care systemEffective treatments such as FabiFlu promise to greatly relieve stress and provide patients in India with a much-needed and timely treatment optionFabiFlu is a 200 mg tablet, the drug will be marketed on prescription drugs, the recommended dose is: the first day morning and evening each take, each dose of 1800 mg (9 tablets);FabiFlu a box of 34 tablets, with a maximum retail price of 3,500 rupees (about $1.34 per tablet), and 122 tablets for a maximum of 14 days of treatment at a cost of 14,000 rupees ($185), Glenmark is working closely with the Indian government and the health care system to quickly deliver FabiFlu to patients across IndiaThe company also plans to conduct another clinical trial to evaluate the efficacy of FabiFlu's combination antiviral drug umifenovir for the treatment of adult patients hospitalized with moderate new coronary pneumonia in Indiaearly May, Japanese Prime Minister Shinzo Abe said the japanese government plans to approve Fabirawe by the end of May if the safety and effectiveness of the fapirave treatment FOR COVID-19 is confirmedHowever, at a press conference at the end of the month, Japan's health minister, Katsunobu Kato, announced the extension of The Target schedule for Fabilavi's approval, after an independent review committee concluded that while most patients treated with Fapilavir in a single arm study had recovered from mild neo-glacine pneumonia, there was no control group that could not clearly prove its effectivenessMoreover, Fapilawe has been shown to be at risk of birth defects in animal studies The committee concluded that clinical results needed to be carefully interpreted and that it was too early to conduct a scientific assessment currently, Fujifilm Group is conducting a Phase III clinical trial in Japan On June 9th the company said it would affect its target of completing the trial by the end of June as the number of people infected in Japan fell rapidly The company is working to increase the number of test sites in order to conclude the project as soon as possible It is reported that Fabirawe is currently in more than 40 countries around the world to carry out COVID-19 clinical testing source: 1, Glenmark wins approval in India for favipiravir in COVID-19 2, Fujifilm's Avigan COVID-19 Trial May Sever into July.